CTNI-33. TARGET TRIAL: A PHASE I/II OPEN-LABEL MULTICENTER STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFICACY OF AZD4547 IN PATIENTS WITH RELAPSED/REFRACTORY FGFR FUSION POSITIVE GLIOMA

Authors: Alberto Picca, Anna Luisa Di Stefano, Julien Savatovsky, Francois Ducray, Olivier Chinot, Elisabeth Cohen-Jonathan Moyal, Paule Augereau, Yohann Schmitt, Julie Lerond, Nabila Rousseaux, Christine Fardeau, Karima Mokhtari, Franck Bielle, David Meyronet, Antonio Iavarone, Marc Sanson

Published: 2023-11-11

DOI: 10.1093/neuonc/noad179.0315

Source: Full article

CTNI-33. TARGET TRIAL: A PHASE I/II OPEN-LABEL MULTICENTER STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFICACY OF AZD4547 IN PATIENTS WITH RELAPSED/REFRACTORY FGFR FUSION POSITIVE GLIOMA

Abstract